Terms: = Kidney tumors AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
448 results:
1. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/pd-l1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract] [Full Text] [Related]
2. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
3. Association of Androgen Receptor and pd-l1 Expression in Upper Urinary Tract Urothelial Carcinoma.
Okuda Y; Kato T; Fujita K; Fushimi H; Miyamoto H; Netto GJ; Nonomura N
Cancer Genomics Proteomics; 2024; 21(2):137-143. PubMed ID: 38423597
[TBL] [Abstract] [Full Text] [Related]
4. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM; Schenker M; Medioni J; Mandziuk S; Majem M; Gravis G; Cornfeld M; Ranganathan S; Lou S; Csoszi T
ESMO Open; 2024 Mar; 9(3):102387. PubMed ID: 38401247
[TBL] [Abstract] [Full Text] [Related]
5. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract] [Full Text] [Related]
6. Integrative Analyses of Tumor and Peripheral Biomarkers in the treatment of Advanced Renal Cell Carcinoma.
Choueiri TK; Donahue AC; Braun DA; Rini BI; Powles T; Haanen JBAG; Larkin J; Mu XJ; Pu J; Teresi RE; di Pietro A; Robbins PB; Motzer RJ
Cancer Discov; 2024 Mar; 14(3):406-423. PubMed ID: 38385846
[TBL] [Abstract] [Full Text] [Related]
7. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
[No Abstract] [Full Text] [Related]
8. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
9. Experience with pembrolizumab in a renal transplant patient with advanced lung cancer: a case report and review.
Fernández Madrigal L; García Samblásand V; Sánchez Escudero L
Anticancer Drugs; 2024 Apr; 35(4):377-382. PubMed ID: 38271682
[TBL] [Abstract] [Full Text] [Related]
10. Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity
Ghosh S; Garige M; Haggerty PR; Norris A; Chou CK; Wu WW; Shen RF; Sourbier C
Cell Cycle; 2024 Jan; 23(1):43-55. PubMed ID: 38263737
[TBL] [Abstract] [Full Text] [Related]
11. Pathological findings directing immunotherapy in renal cell carcinomas.
Gökalp Satıcı FE; Karabulut YY
Immunotherapy; 2024 Mar; 16(4):199-204. PubMed ID: 38214137
[TBL] [Abstract] [Full Text] [Related]
12. Guanylate binding protein 5 triggers NF-κB activation to foster radioresistance, metastatic progression and pd-l1 expression in oral squamous cell carcinoma.
Chiu HW; Lin CH; Lee HH; Lu HW; Lin YK; Lin YF; Lee HL
Clin Immunol; 2024 Feb; 259():109892. PubMed ID: 38185269
[TBL] [Abstract] [Full Text] [Related]
13. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract] [Full Text] [Related]
14. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
[TBL] [Abstract] [Full Text] [Related]
15. Solid tumours showing oligoprogression to immune checkpoint inhibitors have the potential for abscopal effects.
Ito M; Abe S; Adachi S; Oshima Y; Takeuchi A; Ohashi W; Iwata T; Ogawa T; Ota A; Kubota Y; Okuda T; Suzuki K
Jpn J Radiol; 2024 Apr; 42(4):424-434. PubMed ID: 38093137
[TBL] [Abstract] [Full Text] [Related]
16. Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment.
Masel R; Roche ME; Martinez-Outschoorn U
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101514. PubMed ID: 38092473
[TBL] [Abstract] [Full Text] [Related]
17. Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis.
Tariki MS; Barberan CCG; Torres JA; Ruano APC; Ferreira Costa DJ; Braun AC; da Silva Alves V; de Cássio Zequi S; da Costa WH; Fay AP; Torrezan G; Carraro DM; Domingos Chinen LT
Pathol Res Pract; 2024 Jan; 253():154918. PubMed ID: 37995423
[TBL] [Abstract] [Full Text] [Related]
18. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract] [Full Text] [Related]
19. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Roussot N; Fumet JD; Limagne E; Thibaudin M; Hervieu A; Hennequin A; Zanetta S; Dalens L; Fourrier T; Galland L; Jacob P; Bertaut A; Rederstorff E; Chevalier C; Ghirardi S; Gilbert E; Khoukaz A; Martin E; Nicolet C; Quivrin M; Thibouw D; Vulquin N; Truc G; Rouffiac M; Ghiringhelli F; Mirjolet C
BMC Cancer; 2023 Nov; 23(1):1080. PubMed ID: 37946136
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
[Next]
